How will the Broad Institute use its CRISPR patent now that the first cure is here?

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way

Related Keywords

Berkeley ,California ,United States ,United Kingdom ,Massachusetts ,Boston ,Cambridge ,Cambridgeshire ,Germany ,Switzerland ,Swiss ,America ,George Church ,Ulrich Storz ,Erick Lucera ,Jacob Sherkow ,Jennifer Doudna ,Emmanuelle Charpentier ,Feng Zhang ,Vertex Pharmaceuticals ,University Of California ,Broad Institute ,Max Planck Institute ,University Of Illinois College Law ,Editas Medicine ,Illinois College ,Crispr Patent ,Vertex ,Yeditas ,Lawsuit ,